Genentech Receives FDA Approval for Cancer Treatment

By Connor Hart

Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft tissue cancer in adults.

The treatment, called Tecentriq Hybreza, can be injected under the skin through an injection over approximately seven minutes, compared with between 30 minutes and 60 minutes for a standard IV-infusion of Tecentriq, according to Genentech, a member of the Roche Group.

Tecentriq Hybreza combines Tecentriq, used to treat tumor cells and tumor-infiltrating immune cells with a drug-delivery technology that increases the permeability of the tissue under the skin, the company said Thursday.

The FDA approval is based on data from Genentech's Phase IB/III IMscin001 study, according to the company, which showed comparable levels of Tecentriq in the blood, "when administered subcutaneously, and a safety and efficacy profile consistent with the IV formulation."

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

September 12, 2024 20:16 ET (00:16 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.